Volume 68, Issue 9 (6 2010)                   Tehran Univ Med J 2010, 68(9): 497-507 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

B L, A A. Recombinant parathormone and osteoporosis: a review article. Tehran Univ Med J 2010; 68 (9) :497-507
URL: http://tumj.tums.ac.ir/article-1-309-en.html
1- , emrc@tums.ac.ir
Abstract:   (6997 Views)
Osteoporosis is a condition characterized with reduced bone density and destruction of the bone structure. The ideal treatment aims to reduce the risk of fracture while improving the density and structure of the bone. Parathormone (PTH) and its main analogue triparatide (rhPTH [1-34]) is a new class of anabolic medications which accelerates the healing process in the fractured bone through improving bone formation and therefore is used for treating severe osteoporosis. The present review article was designed to report the history, different types, anabolic and catabolic effects, complications, indications and contraindications of the hormone.
Full-Text [PDF 320 kb]   (4578 Downloads)    

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb